Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib + camrelizumab + cryoablation for unresectable intermediate or advanced hepatocellular carcinoma
ChiCTR2100052000Phase 4Not yet recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
donafenibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100052000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052000.